Effect of human umbilical cord-derived mesenchymal stem cells on lung

damage in severe COVID-19 patients: a randomised, double-blind,

placebo controlled phase 2 trial

Lei Shi[1,2]*, Hai Huang[3,4]*, Xuechun Lu[2,5]*, Xiaoyan Yan[6]*, Xiaojing Jiang[7], Ruonan Xu[1],

Siyu Wang[1], Chao Zhang[1,2], Xin Yuan[1,2], Zhe Xu[1,2], Lei Huang[1,2], Jun-Liang Fu[1,2],

Yuanyuan Li[1], Yu Zhang[8,9], Weiqi Yao[9,10], Tianyi Liu[2,11], Jinwen Song[1,2], Liangliang

Sun[4,12], Fan Yang[13], Xin Zhang[2,14], Bo Zhang[7], Ming Shi[1], Fanping Meng[1], Yanning Song[1],

Yongpei Yu[6], Jiqiu Wen[2], Qi Li[2], Qing Mao[2], Markus Maeurer[16,17], Alimuddin Zumla[18],

Chen Yao[6#], Wei-Fen Xie[4,15#], Fu-Sheng Wang[1,2#]

1. Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General

Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.

2. Wuhan Huoshenshan Hospital, Wuhan, China.

3. Department of Respiratory, Changzheng Hospital, Second Military Medical University,

Shanghai, China.

4. Optical Valley Branch of Maternal and Child Hospital of Hubei Province, Wuhan,

China.

5. Department of Hematology, Second Medical Center of Chinese PLA General Hospital,

Beijing, China.

6. Peking University Clinical Research Institute, Peking University First Hospital, Beijing,

China.

7. Department of Infectious Disease, General Hospital of Central Theater Command,

Wuhan, China.

8. VCANBIO Cell & Gene Engineering Corp., Ltd. Tianjin, China.

9. National Industrial Base for Stem Cell Engineering Products, Tianjin, China.

10. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong

University of Science and Technology, Wuhan, China.

11. Key Laboratory of Cancer Center, Fifth Medical Center of Chinese PLA General

Hospital, Beijing, China.

12. Department of Endocrinology and Metabolism, Changzheng Hospital, Second Military

Medical University, Shanghai, China.

13. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong

University of Science and Technology, Wuhan, China.

14. Nursing Department, Fifth Medical Center of Chinese PLA General Hospital, Beijing,

China.

15. Department of Gastroenterology, Changzheng Hospital, Second Military Medical

University, Shanghai, China.

16. Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal.

17. I Med Clinic, University of Mainz, Mainz, Germany.

18. Center for Clinical Microbiology, Division of Infection and Immunity, University

College London, and UCL Hospitals NIHR Biomedical Research Centre, London, UK

* Drs. Lei Shi, Hai Huang, Xuechun Lu and Xiaoyan Yan contributed equally to this

article.

Correspondence to:

Prof. Fu-Sheng Wang, Department of Infectious Diseases, Fifth Medical Center of

Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases,

No.100 Western 4th Ring Road, Beijing 100039, China. fswang302@163.com

Prof. Wei-Fen Xie, Department of Gastroenterology, Changzheng Hospital, Second

Military Medical University, 415 Fengyang Road, Shanghai, 200003, China.

weifenxie@medmail.com.cn

Prof. Chen Yao, Peking University Clinical Research Institute, Peking University First

Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China

yaochen@hsc.pku.edu.cn

Abstract

Objective

To assess the safety and efficacy of human umbilical cord-derived MSCs (UC-MSCs) for

severe COVID-19 patients with lung damage.

Design,

Multicentre, randomised, double-blind, placebo-controlled trial.

Setting

Two hospitals in Wuhan, China, 5 March 2020 to 28 March 2020.

Participants

101 severe COVID-19 patients with lung damage aged between 18–74 years.

Intervention

Patients were randomly assigned at a 2:1 ratio to receive either UC-MSCs (4×10^7 cells

per infusion) or placebo on days 0, 3, and 6.

Main outcome measures

The primary endpoints were safety and an altered proportion of whole lung lesion size

from baseline to day 28, measured by chest computed tomography. Secondary outcomes

were reduction of consolidation lesion sizeand lung function improvement (6-minute walk

test, maximum vital capacity, diffusing capacity). Primary analysis was done in the

modified intention-to-treat (mITT) population and safety analysis was done in all patients

who started their assigned treatment.

Results

100 patients were finally recruited to receive either UC-MSCs (n = 65) or placebo (n = 35).

The patients receiving UC-MSCs exhibited a trend of numerical improvement in whole

lung lesion size from baseline to day 28 compared with the placebo cases (the median

difference was -13.31%, 95%CI -29.14%, 2.13%, P=0.080). UC-MSCs administration

significantly reduced the proportions of consolidation lesion size from baseline to day 28

compared with the placebo (median difference: -15.45%, 95% CI -30.82%, -0.39%,

P=0.043). The 6-minute walk test showed an increased distance in patients treated with

UC-MSCs (difference: 27.00 m, 95% CI 0.00, 57.00, P=0.057). The incidence of adverse

events was similar, and no serious adverse events were observed in the two groups.

Conclusions

UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19

patients with lung damage. A phase 3 trial is required to evaluate effects on reducing

mortality and preventing long-term pulmonary disability.

Trial registration

ClinicalTrials.gov Identifier: NCT04288102

Key Points

Question

Are human umbilical cord-derived mesenchymal stem cells (UC-MSCs) safe and effective therapeutic option for limiting lung damage in severe coronavirus disease 2019 (COVID-19)?

Finding

In this randomised, double-blind, placebo-controlled, phase 2 trial that included 100 COVID-19 patients with lung damage, human UC-MSCs medication showed a trend of improvement in whole lung lesion size and significantly reduced the proportions of consolidation lesions from baseline to day 28 in the treated patients compared with the placebo subjects. The 6-minute walk test showed a longer distance in UC-MSCs than placebo group but without significantly difference. UC-MSCs delivery was well tolerated, with no serious adverse events.

Meaning

Human UC-MSC administration for hospitalized COVID-19 with lung damage is safe. Treatment with human UC-MSC improves the resolution of lung lesions, particularly the consolidation lesions.

Introduction

The Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,[1] causes substantial damage to lungs, ranging from mild respiratory illness to severe acute respiratory syndrome, and death,[2-4] Dysregulated immune responses of both the innate and adaptive immune systems are associated with disease severity, lung damage and long term functional disability.[5-8] There are currently no prophylactic vaccines or effective antiviral agents available to treat COVID-19 and management of COVID-19 patients remains largely symptomatic and supportive therapy.[9] Therefore, there is an urgent need for safe and alternative therapeutic options to mitigate inflammatory organ injury. Currently ongoing clinical trials of immunotherapeutic approaches include convalescent plasma therapy, monoclonal antibodies against interleukin-6, and cellular therapies.[10-12] Mesenchymal stem cells (MSC) are non-hematopoietic cells with immune modulatory, regenerative, and differentiation properties.[13] MSC treatment reduced the pathological changes of the lung and inhibits the cell-mediated immune-inflammatory response induced by the influenza virus in animal models and clinical trials.[14 15] The safety and potential efficacy of MSC have also been evaluated in the patients with acute respiratory distress syndrome (ARDS).[16-19] The immunomodulatory and regenerative properties of MSCs offer potential cellular therapeutic option for limiting lung damage in patients with COVID-19 and require evaluation in randomised controlled. In a phase 1 trial we previously demonstrated that intravenous transfusions of human umbilical cord (UC)-MSCs in patients with moderate and severe COVID-19 were safe and well tolerated (NCT04252118).[20] We now report results of a randomised, double-blind, placebo-controlled trial performed at 2 medical centers in Wuhan, China, evaluating the safety and efficacy of intravenous treatment with UC-MSCs in severe COVID-19 patients with lung damage.

Methods

Trial sites:

This investigator-initiated, randomised, placebo-controlled, double-blind phase II trial was carried out at two COVID-19 designated hospitals in Wuhan city, Hubei Province, China. Patients' follow-up procedures were conducted at a third hospital after discharge. The clinical protocol and statistical analysis plan are available in Supplement 1 and Supplement 2.

Inclusion and Exclusion Criteria

Hospitalised patients with severe COVID-19 with laboratory-confirmed SARS-CoV-2 infection by reverse transcription polymerase chain reaction (RT-PCR) were screened. Patients were eligible if they met any of the following criteria:1) severe COVID-19 diagnosed after onset of disease; 2) chest computed tomography (CT) imaging confirmed pneumonia combined with lung damage. The illness severity of COVID-19 was evaluated in accordance with Guidelines issued by the National Health Commission of China (version 7.0).[21] Briefly, patients with any of the following conditions but without invasive ventilation, shock or other organ failure (need organ support therapy) were considered as severe cases: 1) dyspnoea (respiratory rate $\geq$ 30 times/min); 2) oxygen saturation of 93% or lower on room air; 3) arterial oxygen partial pressure (PaO_2)/fraction of inspired oxygen (FiO_2) $\leq$ 300 mmHg; 4) pulmonary imaging showing that the foci progressed by > 50% in 24-48 hours. The exclusion criteria included patients with shock or COVID-19 combined with any one of other organ failures, those who received invasive ventilation, or patients with any malignant tumour, pregnancy or breastfeeding, or co-infection of other pathogens.

Randomization and masking

Eligible patients were randomly assigned in a 2:1 ratio to receive either UC-MSCs or the

placebo, in addition to standard care, using an interactive web response management system (IWRS). A permutated-block randomisation sequence that was stratified by the trial sites was generated and uploaded to the system. Patients, investigators, and outcome assessors (independent central imaging reviewers) were all blinded to the treatment allocation. Blinding was also ensured by the product marking, with the UC-MSCs and the placebo having a similar appearance and packaging.

A barcode-based product management system (Product Identification Authentication and Tracking System, PIATS) was introduced in this study to manage and track the study products logistics, e.g., preparation, packaging, shipping, storage, and clinical administration to the patients. The application of PIATS could realize the blind label processing by non-informative unique barcodes of the clinical study drug. The concealment of the randomisation sequence could be ensured using PIATS and IWRS.

UC-MSCs preparation, dosage, and safety monitoring

UC-MSCs were prepared by VCANBIO Cell & Gene Engineering Corp, Tianjin, China. Briefly, the MSCs were obtained according to the method described in our previous study.[20] The UC-MSCs used in this study came from one umbilical cord of full-term deliveries (after consultation with the parents of UC donor). The Wharton's Jelly (WJ) tissues were cut into approximately 2 mm^3 pieces from cord tissue and planted upside down on tissue culture flasks (75 cm^2) cultured in DMEM/F12, supplemented with fetal bovine serum (10% FBS, BI, Israel) at 37°C with 5% CO_2. The adherent cells were detached with 1×TrypLE (GIBCO, USA) and then re-plated at a density of approximately 6-8×10^3 cells/cm^2 for further expansion. Master cell bank at passage 2 and working cell bank at passage 4 were set separately. A homogenous population of cultured cells at passage 5 were prepared as UC-MSC product. The culture cells were identified by the minimal criteria suggested by International Society for Cellular Therapy(ISCT): (1) plastic

adherent under tissue culture flask; (2) >95% of the cell population expressed CD105,

CD73 and CD90, and these cells were lack expression (<2% positive) of CD45, CD34,

CD11b, CD19 and HLA-DR as measured by flow cytometry (BD, FACS Calibur, USA); (3)

differentiation potential into osteoblasts, adipocytes and chondroblasts under standard in

vitro differentiating conditions. For each individual MSC batch, cell viability was

examined using both trypan blue and 7-AAD/Annexin V staining by flow cytometry after

preparation in Tianjin and before intravenous transfusion in Wuhan, respectively

(Supplement 3). The cell product has been certified by the National Institutes for Food and

Drug Control of China.

The UC-MSC product was an almost colourless suspension containing 4.0×10^7

MSCs in a volume of 100 ml/bag. The placebo had the same medium and appearance in

packaging and suspension, but without the MSCs. After preparation, both the MSC and

placebo products were shipped to the clinical facilities in an ice box with a real-time

monitoring and alarm device for temperature and location to ensure the best storage

conditions (8–12 □). Shipping of cell products by express railway from Tianjin to Wuhan

took less than 6 hours.

The treatment dose was 4.0×10^7 cells for each procedure, and three procedures were

carried out for each patient on day 0, 3, and 6 after randomisation. Infusion was started

with a standard blood filter tubing set with a pore size of 170 μm. Under

electrocardiographic monitoring, the cell product was infused by gravity within 60 min.

We also monitored continuous pulse oximetry as well as patient's physical signs including

body temperature, pulse, skin color, respiration, and blood pressure during the infusion

period and up to 30 min after infusion.

The incidence and nature of all adverse events were reviewed and assessed by the

investigators to determine whether they were related to the administration of the study

product. Methods for data collection and in-study measurements are described in detail in

Supplement 1.

Imaging and clinical outcomes

All patients underwent high-resolution chest CT examination at baseline, day 10, and day

28. The primary outcome was gauged as a change in the total lesion proportion (%) of the

whole lung volume from baseline to day 28, as measured by chest CT. It was defined as

(total lesion proportion of the whole lung volume at day 28−total lesion proportion of the

whole lung volume at baseline) / total lesion proportion of the whole lung volume at

baseline. The secondary imaging outcomes were a change in the total lesion proportion (%)

of the whole lung volume from baseline to day 10, a change in consolidation and

ground-glass lesion proportion from baseline to day 10, 28 , and change in lung

densitometry at day 10, 28. Lung lesions were evaluated by using the changes in

high-resolution chest CT images and measured by centralised imaging interpretation based

on both lung radiologist analyses and imaging software. The imaging data were derived

from a software-assisted lung volumetry and densitometry procedure (Supplement 1).

Clinical outcomes within 28 days included 6-minute walk test (6-MWT), status of

oxygen therapy maximum forced vital capacity (VC_{max}), diffusion lung capacity for carbon

monoxide (DL_{CO}), modified Medical Research Council Dyspnoea Scale (mMRC), changes

in absolute lymphocyte counts and subsets, as well as plasma cytokine and chemokine

levels. Safety evaluation included adverse events and all-cause mortality. Detailed

definitions and assessment procedures are described in Supplement 1.

Statistical analysis

This study was designed as a phase 2 clinical trial. The limited efficacy information of the

medication in patients with COVID-19 and the exploratory nature of this study meant that

the original target sample size was not justified by statistical calculation and was set as 45

patients, with an allocation ratio of 2:1. Minimal serious adverse events were observed in

our phase 1 trial; therefore, the sample size was expanded to 90, and finalized at 101, to

obtain more data from this study. Sample size adjustments were made in a manner that

maintained the double-blind status of this study and were approved by the institutional

review boards of the two participating hospitals.

There were no pre-defined hypotheses made in this study; therefore, we focused on

description instead of inference for statistical analyses: all statistical tests, confidence

intervals, and P-values were used for exploration, not for inference. For primary outcome

analysis – the change in the total lesion proportion (%) of the whole lung volume from

baseline to day 28 and the difference between the UC-MSC and placebo groups was tested

using wilcoxon rank sum test and the median differences were calculated using the

Hodges–Lehmann estimation (It was also applied to other secondary outcomes which were

not in accordance with normal distribution.). Six category scale and MMRC dyspnea score

were calculated by using ordinal logistic regression model. The modified intention-to-treat

(mITT) population was considered as the primary analysis population and safety analysis

was done in all patients who started their assigned treatment. If the patient missed a chest

CT scan, the last scan's results were carried forward to the missing visit for primary

endpoints in the mITT analysis. Other missing values of secondary endpoints and

per-protocol analyses were not imputed. Statistical analyses were performed using SAS

software, version 9.4 (Cary, NC, USA). The figures were generated using GraphPad Prism

7 software (GraphPad Inc., La Jolla, CA, USA).

Patient and public involvement

No patients were involved in setting the outcome measures, nor were they involved in

developing plans for recruitment, design, or implementation of the study. No patients were

asked to advice on interpretation or writing up the results. All participants will be informed

of the trial results by telephone or email. The trial results will be disseminated to the public

through public media.

Results

Study Population

From March 5, 2020, to March 28, 2020, a total of 288 patients were screened at two

hospitals in Wuhan city. The majority of severe hospitalized COVID-19 patients were at

the convalescent stage and some of them were with progression stage. Among them, 101

eligible patients previously diagnosed as severe COVID-19 type, being referred as the ITT

population, were randomised in a 2:1 ratio (66 to the UC-MSC group and 35 to the placebo

group). One patient in the treatment group withdrew her previously written informed

consent after randomisation and did not receive UC-MSC infusion. Therefore, 65 and 35

patients were treated with UC-MSC or placebo, respectively, who were defined as the

modified intention-to treat (mITT) population, as shown in Figure 1. Some patients missed

the follow-up check on day 28 or received the examination outside of the follow-up

window; therefore, the per-protocol (PP) population included 49 patients in the MSC group

and 25 patients in the placebo group (Supplement 4).

Baseline characteristics

The baseline characteristics were highly consistent between the two groups of patients

in the mITT population (Table 1). Briefly, baseline age, sex, BMI, time from symptom

onset, distribution of comorbidities, concomitant medication, and lesion proportions

assessment from chest CT were matched in the two groups. The median time from

symptoms onset to study baseline was 45.00 (39.00, 51.00) days in the MSC group and

47.00 (41.00, 53.00) days in the placebo group. The most common comorbidity was

hypertension, followed by diabetes. The majority of the patients at baseline has a clinical

status of category 2 or category 3, as shown by evaluation of the Six Category Scale. In

detail, there were 14 (21.54%), 50 (76.92%), and 1 (1.54%) patients in category 2, 3, and 4,

respectively, at baseline in the MSC group; and 10 (28.57%), 25 (71.43%), 0 (0.00%) in

category 2, 3, and 4, respectively, in the placebo group. There were no statistical

differences in laboratory results, including D-dimer, interleukin-6 (IL-6), and C-reactive

protein (CRP) between the two groups.

Imaging and clinical outcomes

To evaluate the difference in the primary endpoint and parts of the secondary endpoints, we

analysed the changes in high-resolution chest CT images and measured the lesions by

using centralised imaging interpretation based on the evaluation of both radiologist

analyses and lung imaging artificial intelligence software. Through comparison of the

Hodges-Lehmann estimator of the total lesion proportion (%) of the whole lung volume,

the median change was -19.40% (95% CI, -53.40%, -2.62%) in the MSC group, and -7.30%

(95%CI, -46.59%, 19.12%) in the placebo group on day 28 from baseline, yielding a

difference of -13.31% (95% CI, -29.14%, 2.13%, *P*= .080) (Figure 2, Table 2, Supplement

5). Interestingly, in the evaluation of the consolidation lesions as a specific lesion type, we

found that the median change from baseline to day 28 were -57.70% (95%CI, -74.95%,

-36.56%) and -44.45% (95% CI, -62.24%, -8.82%) in the MSC and placebo groups,

respectively, leading to a significant difference between the MSC group and placebo group

(95% CI -30.82%, -0.39%, *P*= .043). We also observed decrease in the ground-glass

lesions in the MSC group than the placebo group, although the difference was not

statistically significant. To exclude the effect of missing data on the outcomes of the above

results in some mITT cases, we further analysed the PP population. Almost identical results

between the two groups were obtained, as shown in Supplement 6 and 7.

To compare the restoration of lung function and integrated reserve capability among

the two groups of patients, we examined the 6-MWT on the 28th day after the onset of

treatment and found that 6-minute walking distance was longer in the MSC group (median

420.00 meters [interquartile range (IQR) 392.00,465.00]) than in the placebo group

(median 403.00 meters [IQR 352.00,447.00]) with a 95% CI of 0.00–57.00 (*P*= .057, Table

2). Other parameters including VCmax and DLco, the six-category scale, status of oxygen

therapy and mMRC dyspnoea score were similar between the two groups (Table 2). In

addition, there was no significant difference in the subsets of peripheral lymphocyte counts

(CD4+ T cells, CD8+ T cells, B cells, NK cells) and plasma markers between the two

groups (Supplement 8).

Post Hoc Analyses

We have established five models in three analysis data sets (mITT, PPS and ITT) for

sensitivity analyses of primary end point (Supplement 9). The five models included:

treatment group factor was included in model 1, treatment group and center factors were

included in model 2 as fixed effects, and treatment group, baseline and center factors were

included as fixed effects in model 3, center factor was included as random effect, treatment

group factor was included as fixed effects in model 4, center factor was included as

random effect, treatment group and baseline factors were included as fixed effects in model

5. The conclusions of all models were consistent with those of univariate analysis.

Safety

The incidence of adverse events reported during the study was similar in the MSC group

(55.38%) and the placebo group (60%) (Table 3). The most common adverse event in the

MSC group was an increase in lactic acid dehydrogenase (13.85%), compared with 20% in

the placebo group; a 10.77% elevation of serum alanine aminotransferase compared with

11.43% in the placebo group; a 9.23% increase in hypokalaemia compared with 2.86% in

the placebo group; a 7.69% increase in aspartate aminotransferase compared with 11.43%

in the placebo group; and a 7.69% increase in hyperuricemia compared with 8.75% in the

placebo group. Only one case experienced a grade 3 adverse event (pneumothorax) in the

MSC group, which recovered spontaneously under conservative treatment. There were few

other adverse events at grade 1 or 2 in both groups. All adverse events during the

observation period were judged by the site investigators and found to be unrelated to

UC-MSC intervention. No deaths were observed in this trial.

Discussion

Whilst several trials of the therapeutic use of MSCs for patients with COVID-19 have been

registered at Clinicaltrial.gov, there are no data available to date from randomised

placebo-controlled clinical trials yet. This is the first report of a double-blind, randomised,

and controlled phase 2 trial, in COVID-19 patients with lung damage. Our data found that

UC-MSC administration was safe and well tolerated and exerted a trend of improvement in

whole lung lesion for COVID-19 patients. More interestingly, UC-MSC medication

significantly increased the resolution of lung consolidation lesions compared with the

placebo. The data from the 6-MWT data show an improved restoration of the integrated

reserve capability in the UC-MSC-treated patients. These findings indicate that the use of

UC-MSC as adjunctive therapy to standard of care treatment for patients with COVID-19

is a viable option. Recently, MSCs have been approved conditionally by the US-FDA

under what is known as 'expanded access compassionate use' for COVID-19 patients. A

phase 3 trial is now required to further evaluate effects on mortality and long term

pulmonary disability, and to determine the underlying mechanisms of UC-MSC treatment

for COVID-19 disease.[22]

COVID-19 is characterized by pathological lung changes in both the parenchyma

and interstitium[2], including ground glass opacity, consolidation, traction bronchiectasis,

reticulation, and thickening of the bronchovascular bundles, as imaged using chest CT[23].

Notably, the improvement of pulmonary lesions, especially the improvement of pulmonary

interstitial lesions, directly affects the recovery of lung function and the remission of

clinical symptoms.[24] The outbreak of COVID-19 occurred in China in January and early

February, and was basically brought under control in March. As enrolment ensured, many

severe hospitalized COVID-19 patients were at the convalescent stage and some of these

patients in the progression stage, which presented a challenge to explore clinical

improvement. Considering lung damage was still a common characteristic in these patients

at convalescent phase which affected their recovery and life quality, we modified the

primary outcome to the change in the total lesion proportion (%) of the whole lung volume

as measured by CT from baseline to day 28. The patients enrolled in this study were all

previously diagnosed as severe types, with a longer disease course and older age,

compared with the recent studies.[25,26] In particular, all the patients suffered from serious

pulmonary damage and needed oxygen inhalation support during the course of disease. Our

current trial showed that UC-MSCs therapy improved the resolution of the whole lung

damage size, as detected by CT scanning, particularly the consolidation lesions. This finding

indicated that UC-MSC administration has a therapeutic benefit for patients with

COVID-19, even in the convalescent stage. It is known that the consolidation lesions in the

lung include the interstitial fibrosis. Thus, the improvements of consolidation lesions might

also imply the alleviation of lung fibrosis.

The 6-MWT has been used to evaluate patients suffering from a variety of

cardiopulmonary diseases. The results reflect the integrated reserve capability of complex

physiology, involving the pulmonary and cardiovascular systems, and neuromuscular

circulation[27]. In this trial, the 6-MWT was numerically, but not statistically, improved in

the MSC group compared with that in the placebo group. Given that there was no

significant difference in cardiovascular diseases between the two groups and no

cerebrovascular diseases in both groups at baseline, the findings from the 6-MWT data

imply that capacity for aerobic exercise was potentially improved in the UC-MSCs group.

It is hypothesized that the beneficial effect of MSC treatment for patients with severe

COVID-19 is mediated via reduction of pro-inflammatory cytokines, that jointly mediate

immune pathology and worsen clinical COVID-19 outcomes.[7,28-30] Cytokines such as

serum IL-6 are considered as biologically relevant biomarkers associated with disease

progression of COVID-19. In this study, UC-MSC infusion did not result in a significant

reduction in the duration of oxygen therapy, mMRC, cytokine, or chemokine levels, which

might be in part attributed to the status of the enrolled population, since most of them were

not in the acute progressive stage. Other mechanisms of actions have to be explored for

MSCs that are measurable in the systemic circulation. We could not, however, measure the

local, i.e. intrapulmonary, effects of MSC delivery. It could very well be that the local

MSC-mediated effects were not measurable in the systemic circulation, a similar scenario

as in MSC treatment of patients with corticosteroid-resistant graft-versus-host-disease

(GVHD).

In our trial, a total of three doses of 4×10^7 UC-MSCs were transfused for each

patient. No MSC-related predefined haemodynamic or respiratory adverse events were

observed. The incidences of adverse events were similar between the MSC group and the

placebo group. Only one patient in the MSC group suffered a pneumothorax that was

judged to be unrelated to UC-MSC medication. No patient died during the follow-up period.

The safety profile of the UC-MSCs confirms the results of our previous phase 1 trial[20] and

other MSC studies.[31,32] These data suggested that UC-MSC therapy was well tolerated and

very safe. In view of the ongoing clinical trials with higher dose of MSCs used in other

groups in China, America, and Europe,[22] more safety data are expected in the near future.

Limitations

There were several operational limitations to our study. A larger sample size could

have improved efficacy analyses. According to management guidelines issued by the

Chinese National Health Commission (7th edition),[21] patients with COVID-19 require

further centralized isolation for 14 days after discharge. In this setting, some of the patients

missed the follow-up data at day 28, but they did receive a follow-up check around 7–10

days after the 28-day follow-up window. Importantly, our PP population analysis also

revealed similar results compared with mITT population analysis. Whether the cell dosage,

interval duration, and cycles of UC-MSC medication were the best regimen for patients

with severe COVID-19 were not fully investigated in this study.

Conclusion and future implications

To the best of our knowledge, this is the first randomised, double-blind,

placebo-controlled trial evaluating the safety and preliminary efficacy of UC-MSCs as a

potential treatment for patients with COVID-19 with lung damage, even at the

convalescent stage.   UC-MSC administration was safe and accelerated resolution of lung

consolidation lesions and improvement in the integrated reserve capability after UC-MSC

administration. UC-MSCs treatment offers a safe and potentially effective therapeutic

approach for COVID-19 patients with lung damage. A phase 3 trial is required to further

evaluate effects on preventing long-term pulmonary disability, reducing mortality and

determining the underlying mechanisms of UC-MSC treatment for COVID-19 disease.

Contributions

FSW ideated and led the study. FSW, WFX, CY and LS designed the study and developed the protocol. LS, HH, XCL, XY, ZX, LH, JLF and LLS were responsible for study enrolment. LS, XCL, XY, ZX, LH, JLF were responsible for acquisition, analysis, and interpretation of data. YZ, WQY, CZ, TYL and JWS were responsible for biorepository management and biomarker analyses. All authors made substantial contributions to conduct and coordination of trial and had regular discussions on progress of the study. CY, YXY and YPY contributed to statistical analysis. LS, RNX and CZ wrote the initial manuscript draft, and FSW, WFX, MM and AZ critically revised the manuscript. All authors edited, read and approved the final version before submission.

Funding

This trial was supported by The National Key R&D Program of China (2020YFC0841900, 2020YFC0844000, 2020YFC08860900); The Innovation Groups of the National Natural Science Foundation of China (81721002); The National Science and Technology Major Project (2017YFA0105703). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Competing interests

All authors declare no competing interests.

Ethical approval

This study was approved by the Clinical Trial Ethics Committee of Fifth Medical Cente, Chinese PLA General Hospital (2020-013-D), the Medical Ethics Committee of Wuhan Huoshenshan Hospital(HSSLL004), the Medical Ethics Committee of Maternal and Child Hospital of Hubei Province(2020IEC001).Written informed consent was obtained from all the enrolled patients or their legal representatives if they were unable to provide consent.

Data sharing

After approval from the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed. See Supplement 12.

Transparency declaration

The lead author* affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities

Participants will be informed of the results of the study by telephone or mail. Dissemination to the public will be achieved through media outreach.

Acknowledgements

F-S.W, C.Z, M.M., and A.Z. are founder members of the Global Cancer and Infectious Diseases consortium for Host-Directed therapies (https://www.fchampalimaud.org/covid19/aci/)

Additional Contributions

We thank Drs. Sibing Zhang, Dixiong Xu, Fangguo Dai and Bin Liu for logistic support

and valuable suggestions to the clinical study. We also thank Fang Lian, Baoqiang Fu,

Yingying Gao and Yan Zhang for their excellent work in follow-up of all enrolled patients.

We thank randomization system provider (Chengdu Cims-medtech), PIATS provider

(Alibaba Health Technology) and academic secretaries (Yufeng Guo, Hairui Si, Lvshuai

Huang, Junqing Luan) for their services. We also thank the People's Government of

Wuhan Municipality for the help in organizing the follow-up work.

References

1. WHO. Coronavirus disease (COVID-2019) situation reports 2020 [Available from:
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute
respiratory distress syndrome. Lancet Respir Med 2020;8(4):420-22. doi:
10.1016/S2213-2600(20)30076-X [published Online First: 2020/02/23]

3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. doi:
10.1016/S0140-6736(20)30183-5 [published Online First: 2020/01/28]

4. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor
prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost
2020;18(4):844-47. doi: 10.1111/jth.14768 [published Online First: 2020/02/20]

5. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients
reveals distinct immunotypes with therapeutic implications. Science 2020 doi:
10.1126/science.abc8511 [published Online First: 2020/07/17]

6. Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune
perturbations associated with severe COVID-19. Sci Immunol 2020;5(49) doi:
10.1126/sciimmunol.abd7114 [published Online First: 2020/07/17]

7. Song JW, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and
severe cases of COVID-19. Nat Commun 2020;11(1):3410. doi:
10.1038/s41467-020-17240-2 [published Online First: 2020/07/10]

8. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the
Science. Immunity 2020;52(6):910-41. doi: 10.1016/j.immuni.2020.05.002 [published
Online First: 2020/06/09]

9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,
and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York
City Area. JAMA 2020 doi: 10.1001/jama.2020.6775 [published Online First:
2020/04/23]

10. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with

Covid-19 - Preliminary Report. N Engl J Med 2020 doi: 10.1056/NEJMoa2021436

[published Online First: 2020/07/18]

11. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical

Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized

Clinical Trial. JAMA 2020 doi: 10.1001/jama.2020.10044 [published Online First:

2020/06/04]

12. Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center

experience. J Med Virol 2020;92(7):814-18. doi: 10.1002/jmv.25801 [published

Online First: 2020/04/08]

13. Galipeau J, Sensebe L. Mesenchymal Stromal Cells: Clinical Challenges and

Therapeutic Opportunities. Cell Stem Cell 2018;22(6):824-33. doi:

10.1016/j.stem.2018.05.004 [published Online First: 2018/06/03]

14. Chan MC, Kuok DI, Leung CY, et al. Human mesenchymal stromal cells reduce

influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci

U S A 2016;113(13):3621-6. doi: 10.1073/pnas.1601911113 [published Online First:

2016/03/16]

15. Chen J, Hu C, Chen L, et al. Clinical study of mesenchymal stem cell treating acute

respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a

hint for COVID-19 treatment. Engineering (Beijing) 2020 doi:

10.1016/j.eng.2020.02.006 [published Online First: 2020/04/16]

16. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal

stromal cells for moderate to severe acute respiratory distress syndrome (START

study): a randomised phase 2a safety trial. Lancet Respir Med 2019;7(2):154-62. doi:

10.1016/S2213-2600(18)30418-1 [published Online First: 2018/11/21]

17. Simonson OE, Mougiakakos D, Heldring N, et al. In Vivo Effects of Mesenchymal

Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.

Stem Cells Transl Med 2015;4(10):1199-213. doi: 10.5966/sctm.2015-0021 [published

Online First: 2015/08/20]

18. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of

ARDS: a phase 1 clinical trial. Lancet Respir Med 2015;3(1):24-32. doi:
10.1016/S2213-2600(14)70291-7 [published Online First: 2014/12/23]

19. Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome
with allogeneic adipose-derived mesenchymal stem cells: a randomised,
placebo-controlled pilot study. Respir Res 2014;15:39. doi: 10.1186/1465-9921-15-39
[published Online First: 2014/04/09]

20. Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell
therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target
Ther 2020;5(1):172. doi: 10.1038/s41392-020-00286-5 [published Online First:
2020/08/29]

21. China NHCo. New coronavirus pneumonia prevention and control program (7th edn)
[updated March 4, 2020. Available from:
http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.sht
ml.

22. Zumla A, Wang FS, Ippolito G, et al. Reducing mortality and morbidity in patients with
severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem)
Cell (MSC) therapy - Achieving global consensus and visibility for cellular
host-directed therapies. Int J Infect Dis 2020;96:431-39. doi:
10.1016/j.ijid.2020.05.040 [published Online First: 2020/05/20]

23. Yang Q, Liu Q, Xu H, et al. Imaging of coronavirus disease 2019: A Chinese expert
consensus statement. Eur J Radiol 2020;127:109008. doi: 10.1016/j.ejrad.2020.109008
[published Online First: 2020/04/27]

24. Antoine M, Mlika M. Interstitial Lung Disease. StatPearls. Treasure Island (FL)2020.

25. Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and
outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an
observational study. Lancet Respir Med 2020;8(9):853-62. doi:
10.1016/S2213-2600(20)30316-7 [published Online First: 2020/08/01]

26. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in
hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:

prospective observational cohort study. BMJ 2020;369:m1985. doi:

10.1136/bmj.m1985 [published Online First: 2020/05/24]

27. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test.

Am J Respir Crit Care Med 2002;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102

[published Online First: 2002/07/02]

28. Chen B, Tian EK, He B, et al. Overview of lethal human coronaviruses. Signal

Transduct Target Ther 2020;5(1):89. doi: 10.1038/s41392-020-0190-2 [published

Online First: 2020/06/14]

29. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. Immunity

2020 doi: 10.1016/j.immuni.2020.06.017 [published Online First: 2020/07/02]

30. Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological responses

in patients with COVID-19. Nat Immunol 2020 doi: 10.1038/s41590-020-0762-x

[published Online First: 2020/08/14]

31. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells

Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis

2020;11(2):216-28. doi: 10.14336/AD.2020.0228 [published Online First: 2020/04/08]

32. Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the

treatment of patients with severe COVID-19. Front Med 2020 doi:

10.1007/s11684-020-0810-9 [published Online First: 2020/08/08]

Figure 1: Trial profile

ITT = intention-to treat population. mITT = modified intention-to treat population

Figure 2. Decline in total and consolidation lesion proportion (%) between the

umbilical cord-mesenchymal stem cell (UC-MSC) group and placebo group at 28

days.

A. Panel A shows the between-group median difference in the change in total lesion

proportion (%) and consolidation lesion proportion (%) of the whole lung volume from

baseline to day 28. I bars indicate the 95%CI described by Hahn and Meeker (1991).

B. Panel B shows box plots of the change in the total lesion proportion (%) and

consolidation lesion proportion (%) of the whole lung volume from baseline to day 28.

Q1 denotes the first quartile, and Q3 the third quartile. I bars indicate the minimum and

maximum.

C. Panel C shows the mean absolute change from baseline in the total lesion proportion (%)

and consolidation lesion proportion (%) of the whole lung volume. I bars indicate the

standard error.

Figure 1

Figure 1: Trial profile

ITT= intention-to treat population. mITT= modified intention-to treat population

Figure 2

Figure 2. Decline in total and consolidation lesion proportion (%) between the MSC group and placebo group at 28 day.

A. Panel A shows the between-group median difference in the change in total lesion proportion (%) and consolidation lesion proportion (%) of the whole lung volume from baseline to day 28. I bars indicate the 95%CI described by Hahn and Meeker (1991).

B. Panel B shows box plots of the change in the total lesion proportion (%) and consolidation lesion proportion (%) of the whole lung volume from baseline to day 28. Q1 denotes the first quartile, and Q3 the third quartile. I bars indicate the minimum and maximum.

C. Panel C shows the mean absolute change from baseline in the total lesion proportion (%) and consolidation lesion proportion (%) of the whole lung volume. I bars indicate the standard error.

Table 1: Baseline patient characteristics.

	UC-MSC group (n = 65)	Placebo group (n = 35)
Age, years	60.72(9.14)	59.94(7.79)
Sex – no. (%)		
Men	37 (56.92%)	19 (54.29%)
Women	28 (43.08%)	16 (45.71%)
BMI (Body Mass Index), Kg/m^2*	24.71(3.19)	25.01(3.12)
Time from symptom onset to baseline, days	45.00(39.00,51.00)	47.00(41.00,53.00)
Any comorbidities	34 (52.31%)	18 (51.43%)
Hypertension	17 (26.15%)	10 (28.57%)
Diabetes	12 (18.46%)	5 (14.29%)
Chronic bronchitis	2(3.08%)	3(8.57%)
Chronic obstructive pulmonary disease	2(3.08%)	0(0.00%)
Concomitant medication		
Antiviral drugs	32 (49.23%)	20 (57.14%)
Antibiotics	27 (41.54%)	12 (34.29%)
Corticosteroids	13 (20.00%)	9 (25.71%)
Lesion proportion (%): total lesion volume (in cm^3) / whole lung volume (in cm^3)	26.31(11.62,38.42)	27.98(11.57,44.14)
Consolidation lesion proportion (%): Consolidation lesion volume (in cm^3) / whole lung volume (in cm^3)	2.59(0.69,5.20)	2.52(0.77,4.91)
Six-category scale		
2-Hospitalized, not requiring supplemental oxygen	14 (21.54%)	10 (28.57%)
3-Hospitalized, requiring supplemental oxygen	50 (76.92%)	25 (71.43%)
4-Hospitalized, on noninvasive ventilation or high flow oxygen devices	1 (1.54%)	0 (0.00%)
White blood cell count* (10^9/L)	5.70(5.00,6.60)	5.80(5.00,6.80)
Lymphocyte count (10^9/L)	1.39(1.19,1.80)	1.47(1.24,1.84)
CD4 T cells (/μl) †	641.00(482.00,760.00)	734.00(502.00,1031.00)
CD8 T cells (/μl) †	371.00(275.00,520.00)	401.00(307.00,593.00)
B cells (/μl) †	148.50(99.60,251.00)	148.50(94.70,248.00)

NK cells (/µl) †	233.50(151.00,393.00)	197.50(136.00,309.00)
Neutrophil count (10^9/L)	3.48(2.91,4.32)	3.83(2.85,4.48)
Platelet count (10^9/L)	214.00(174.00,255.00)	210.00(176.00,247.00)
Hemoglobin （g/L）	122.68 (14.44)	124.26 (11.83)
D-dimer (mg/L) ‡	0.58 (0.36,1.11)	0.56 (0.31,1.12)
IL-6 (pg/ml) §	7.86(5.63,9.84)	8.76(6.54,11.77)
CRP(mg/L) ¶	1.95(0.84,3.53)	1.38(0.68,2.26)
SARS-CoV-2 test result‖		
SARS-Cov-2 IgG positive	63 (100.00%)	34 (100.00%)
SARS-Cov-2 IgM positive	58 (92.06%)	32 (94.12%)
SARS-Cov-2 nucleic acid detection positive	47(72.31%)	20(57.14%)

Data are median (interquartile range (IQR)), n (%),or mean (SD)

* BMI values were available for 59 patients in the UC-MSC group and 33 patients in the placebo group.

† CD4, CD8, CD19, and CD56 values were available for 62 patients in the UC-MSC group and 34 patients in the placebo group.

‡ D-dimer values were available for 55 patients in the UC-MSC group and 29 patients in the placebo group.

§ IL-6 values were available for 64 patients in the UC-MSC group and 35 patients in the placebo group.

¶ CRP values were available for 27 patients in the UC-MSC group and 14 patients in the placebo group.

‖ The test results are summarized from hospitalization to the pre-random test. If there is any positive, it is defined as positive. The

IgG and IgM values were available for 63 patients in the UC-MSCs group and 34 patients in the placebo group.

Table 2: Primary and secondary outcomes in the mITT population.

	UC-MSC group (n = 65)	Placebo group (n = 35)	Difference
Change in the total lesion proportion (%) of the whole lung volume from baseline to day 28	-19.40(-53.40, -2.62)	-7.30(-46.59,19.12)	-13.31(-29.14,2.13) †
Change in consolidation lesion proportion (%) of whole lung volume from baseline to day 28	-57.70(-74.95, -36.56)	-44.45(-62.24, -8.82)	-15.45(-30.82, -0.39) †
Change in ground-glass lesion proportion (%) of whole lung volume from baseline to day 28	-14.95(-51.55,7.29)	-3.94(-43.99,32.55)	-9.84(-30.51,6.86) †
6-minute walking distance at day 28 (meters) *	420.00 (392.00, 465.00)	403.00 (352.00, 447.00)	27.00 (0.00, 57.00) †
VCmax(L) at day 28 ¶	2.57 (2.13, 3.04)	2.49 (2.05, 2.76)	0.16 (−0.10, 0.43) †
DLco (L) at day 28‖	5.12 (1.62)	5.06 (1.57)	0.07 (−0.69, 0.82)
Six-category scale at day 10			0.77(0.33,1.79) &
1-Not hospitalised;	11(16.92%)	6(17.14%)	
2-Hospitalized, not requiring supplemental oxygen	8(12.31%)	6(17.14%)	
3-Hospitalized, requiring supplemental oxygen	44(67.69%)	23(65.71%)	
4-Hospitalized, on noninvasive ventilation or high flow oxygen devices	2(3.08%)	0(0.00%)	
Duration of oxygen therapy (days) ‡	22.00(13.00,32.00)	31.00(16.00,36.00)	-7.00(-17.00,3.00) †
Finger pulse oxygen in resting state (%) at day 28 §	97.10(1.31)	96.97(1.29)	0.13(-0.42,0.68)
mMRC dyspnea score at day 28 **			1.49(0.68,3.26) &
Grade 0 n(%)	29(47.54%)	13(37.14%)	
Grade 1 n(%)	24(39.34%)	16(45.71%)	
Grade 2 n(%)	5(8.20%)	4(11.43%)	
Grade 3 n(%)	3(4.92%)	1(2.86%)	
Grade 4 n(%)	0(0.00%)	1(2.86%)	

Data are median (interquartile range, IQR), mean (SD) or n (%).

* In the 6-minute walk test, there were three cases who could not complete the test because of cardiopulmonary function problems. The data were calculated as 0 meters.

† Differences are expressed as Hodges-Lehmann estimator and 95% confidence interval (CI).

¶ VCmax (L) at day 28 were available for 53 patients in the UC-MSC group and 31 patients in the placebo group.

‖ DLco (L) at day 28 were available for 53 patients in the UC-MSC group and 27 patients in the placebo group.

&Calculated by ordinal logistic regression model. OR=odds ratio.

‡ Duration of oxygen therapy (days) were available for 29 patients in the UC-MSCs group and 11 patients in the placebo group.

§ Finger pulse oxygen in resting state (%) at day 28 were available for 61 patients in the UC-MSCs group and 35 patients in the placebo group.

** mMRC dyspnea scores were available for 61 patients in the UC-MSCs group and 35 patients in the placebo group.

Table 3. Summary of adverse events that occurred in the enrolled population of the trial.

	UC-MSC group (n = 65)		Placebo group (n = 35)	
	Grade 1 or 2	**Grade 3 or 4**	**Grade 1 or 2**	**Grade 3 or 4**
Any adverse event	36 (55.38%)	1 (1.54%)	21 (60.00%)	0 (0.00%)
Increased lactic acid dehydrogenase	9(13.85%)	0(0.00%)	7(20.00%)	0(0.00%)
Increased alanine aminotransferase	7(10.77%)	0(0.00%)	4(11.43%)	0(0.00%)
Hypokalaemia	6(9.23%)	0(0.00%)	1(2.86%)	0(0.00%)
Increased aspartate aminotransferase	5(7.69%)	0(0.00%)	4(11.43%)	0(0.00%)
Increased serum uric acid	5(7.69%)	0(0.00%)	3(8.57%)	0(0.00%)
Diarrhoea	4(6.15%)	0(0.00%)	0(0.00%)	0(0.00%)
Palpitations	3(4.62%)	0(0.00%)	0(0.00%)	0(0.00%)
Increased γ -glutamyl transferase	2(3.08%)	0(0.00%)	1(2.86%)	0(0.00%)
Dizziness	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Cough	2(3.08%)	0(0.00%)	1(2.86%)	0(0.00%)
abdominal distention	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Anemia	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Pneumothorax	0(0.00%)	1(1.54%)	0(0.00%)	0(0.00%)
Metabolic alkalosis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Urinary tract infection	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Bacterial infection	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pharyngitis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Increased heart rate	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Creatine phosphate stimulation	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Elevated blood urea	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Poor sleep quality	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Taste reversal	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Chest musculoskeletal	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pulmonary edema	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pharyngeal diseases	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)

Anxious	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Nervous	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Rash	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Thirsty	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Nausea	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Countercurrent	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Non infectious gingivitis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Abdominal pain	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Functional gastrointestinal turbulence	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Vomit	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Gastroesophageal reflux disease	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Toothache	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
heart failure	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Hypocalcemia	0(0.00%)	0(0.00%)	2(5.71%)	0(0.00%)
Hepatic cyst	0(0.00%)	0(0.00%)	2(5.71%)	0(0.00%)
Creatine phosphate stimulation	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Elevated serum creatinine	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Respiratory alkalosis	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Pleural effusion	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Difficulty in falling asleep	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Pruritus	0(0.00%)	0(0.00%)	3(8.57%)	0(0.00%)